Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model.

Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model. Abstract Text:

Yoshinobu Ueno,Takashi Ohmi,Mitsuko Yamamoto,Naoto Kato,Yukiko Moriguchi,Midori Kojima,Rieko Shimozono,Sachiko Suzuki,Tomomi Matsuura,Hiroyuki Eda,Yoshinobu Ueno,Takashi Ohmi,Mitsuko Yamamoto,Naoto Kato,Yukiko Moriguchi,Midori Kojima,Rieko Shimozono,Sachiko Suzuki,Tomomi Matsuura,Hiroyuki Eda,

In a mouse model of alpha-Fas-induced acute liver injury, the orally-administered caspase inhibitor PF-03491390 (formerly named IDN-6556) was retained in the liver for prolonged periods with a low systemic exposure. Reductions in the elevated plasma levels of alanine aminotransferase (ALT) revealed that the retention of PF-03491390 in the liver exerted a hepatoprotective effect, even when pre-administered to mice 4 h before alpha-Fas insult. Prolonged retention of PF-03491390 in the liver after oral administration has the benefit of low systemic exposure, making this a beneficial agent for the treatment of liver diseases.

Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model. Publishing Authors By Initials

Y Ueno,T Ohmi,M Yamamoto,N Kato,Y Moriguchi,M Kojima,R Shimozono,S Suzuki,T Matsuura,H Eda,Y Ueno,T Ohmi,M Yamamoto,N Kato,Y Moriguchi,M Kojima,R Shimozono,S Suzuki,T Matsuura,H Eda,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of pharmacological sciences

VOLUME: 105

Page Numbers: 201-5

Journal Abbreviation: J. Pharmacol. Sci.

ISSN: 1347-8613

DAY: 6

MONTH: 10

YEAR: 2007

Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101167001

Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model.

AFFILIATION: Discovery Biology Research, Global Research and Development, Nagoya Laboratories, Pfizer Japan, Inc., Taketoyo, Aichi, Japan.

Country: Japan

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Pharmacol Sci

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model Related Publications

• Contribution of Active and Inactive States of the Human 5-HT(4d) Receptor to the Functional Activities of 5-HT(4)-Receptor Agonists.
• Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model.
• [A method of proximal anastomosis with a new assist device]